Azipro

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azipro

Property Description
Active Ingredient Azithromycin dihydrate (INN)
Form Tablet, Capsule, Suspension, Injectable Solution
Pharmacological Class Antibiotic (Macrolide / Azalide)
Common Use Treatment of systemic bacterial infections
Origin Semi-synthetic (derived from Erythromycin)

What is Azipro? Definition and Pharmaceutical Identity

Azipro is the pharmaceutical product containing the active ingredient Azithromycin (INN), a potent, semi-synthetic substance classified as a prescription-only antibiotic used to manage bacterial infections. Azithromycin belongs to the broader macrolide family of antimicrobials and is precisely categorized as an azalide (15-membered ring). This structural distinction provides advantageous properties, including a prolonged half-life and the ability to achieve high, sustained concentrations in body tissues. This chemical design allows for better gastrointestinal stability and reduced interaction with liver enzymes compared to earlier compounds in its class. This structural difference helps the medicine remain effective for a longer time after it is taken.


Azipro Composition and Available Forms

The medication is produced as a single-ingredient product (monocomponent), featuring Azithromycin dihydrate as its active component, alongside various inert excipients tailored for its stability in diverse formulations. Azipro is manufactured in several high-level dosage forms, facilitating both oral and intravenous administration to suit varied patient needs. For instance, the oral suspension form is often used for patient groups who have difficulty swallowing solid tablets. These forms include the common presentations: the tablet, capsule, oral suspension (prepared from powder for suspension), and the injectable solution (prepared from powder for solution for injection).


General Purpose: How Azipro Fights Infection

The general purpose of Azipro is to halt the progression of systemic bacterial infections throughout the body by exerting a specialized antimicrobial action. It achieves this by selectively binding to the bacterial ribosomes, specifically the 50S subunit, which prevents the microbes from synthesizing proteins vital for their growth and division. This mechanism results in a bacteriostatic effect, meaning it prevents the bacteria from multiplying. The primary pharmacological role of the medication is the elimination of bacteria susceptible to this protein synthesis inhibition mechanism. This confirms that the drug’s main function is to stop bacteria from multiplying.

What side effects are possible with Azipro?

Possible Side Effects and Safety Information

The official safety profile for Azipro (Azithromycin) details adverse reactions by frequency and physiological system, based strictly on regulatory classifications. The most frequently documented effects are generally classified as common (affecting up to 1 in 10 patients) and involve the gastrointestinal system, including diarrhea, nausea, abdominal pain, and vomiting. Headache is also reported as a common adverse reaction.


Serious and Organ-Specific Safety Concerns

Regulatory documentation highlights rare but serious adverse reactions

across major organ systems. These include cardiovascular risks, specifically prolonged QT interval that may lead to potentially fatal arrhythmias like Torsades de pointes, with the highest potential risk noted during the initial five days of use. Hepatobiliary disorders documented range from abnormal liver function to rare cases of hepatic failure (sometimes fatal). Additionally, severe, life-threatening allergic and dermatological reactions, such as Anaphylaxis, Toxic Epidermal Necrolysis (TEN), and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), are officially reported.


Population-Specific Notes and Safety Patterns

Specific safety considerations are defined for certain groups. For neonates and infants (up to 42 days of life), there is an association with Infantile Hypertrophic Pyloric Stenosis (IHPS). Geriatric patients may exhibit increased susceptibility to Torsades de pointes arrhythmias. Safety restrictions formally contraindicate the use of Azipro in individuals with a history of cholestatic jaundice or liver dysfunction previously associated with Azithromycin. Furthermore, regulatory documents note that delayed-onset reactions, such as Clostridioides difficile-associated diarrhea (CDAD), can occur up to two months after administration, and allergic symptoms may reappear due to the drug's prolonged tissue presence.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes an Azipro overdose as primarily involving an exaggeration of known adverse effects of the macrolide class of antibiotics. Symptoms experienced following exposure to higher than recommended doses are similar to those seen at normal therapeutic doses but may become more severe.

Documented Overdose Symptoms

The documented physiological systems affected are the gastrointestinal tract and the cardiac system. Overdose symptoms may include severe instances of:

  • Severe Nausea
  • Vomiting
  • Diarrhea

When to Seek Immediate Medical Attention

Urgent medical help is required in situations where severe adverse effects may indicate an acute overdose or serious reaction. According to official labeling, you must seek immediate care if any of the following occur while taking azithromycin:

  • Irregular heartbeat (arrhythmia)
  • Shortness of breath
  • Dizziness or fainting

Furthermore, if the victim has collapsed, had a seizure, has trouble breathing, or can't be awakened, emergency services should be called immediately.

Official Overdose Management

In the event of an overdose, management is primarily supportive and symptomatic. The administration of medicinal charcoal and general symptomatic treatment and supportive measures are indicated as required to manage the patient's condition following exposure.

Therapeutic Uses of Azipro

Azipro: Main Uses and Benefits

Quick Facts: Therapeutic Domains

  • May address respiratory infections such as community-acquired pneumonia and acute bacterial sinusitis.
  • Used to manage specific sexually transmitted infections (STIs).
  • An option for certain uncomplicated skin and skin structure infections.

Azipro is a prescribed therapy option indicated for managing a range of bacterial infections. Its uses focus on several key therapeutic domains based on the susceptibility of the causative microorganisms. This medication may be prescribed to address infections of the respiratory tract, including acute bacterial exacerbations of chronic bronchitis and pharyngitis/tonsillitis, especially when first-line therapies cannot be used.

In addition, Azipro may be utilized to manage specific sexually transmitted infections, such as those causing urethritis, cervicitis, and genital ulcer disease in men. It is also an option for managing uncomplicated infections affecting the skin and soft tissues. A healthcare professional determines the appropriate use of Azipro for the specific condition presented, prioritizing use only when the infection is proven or strongly suspected to be bacterial in nature. Azipro may also be part of a comprehensive regimen for the management or prevention of Mycobacterium avium complex (MAC) disease in certain individuals.

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Azipro (Azithromycin)

This eligibility profile is based strictly on official government regulatory documents (e.g., FDA, EMA) and outlines the populations who may use Azipro and those who are formally excluded or require special caution.

Contraindications and Absolute Exclusions

Category Regulatory Status Description
Hypersensitivity Contraindicated Patients with known allergy to azithromycin, erythromycin, or any macrolide/ketolide antibiotic.
Prior Liver Toxicity Contraindicated History of cholestatic jaundice or liver dysfunction associated with previous azithromycin use.

Restricted and Conditional Use

Azithromycin use requires caution and special consideration in specific populations:

  • Cardiac Risk: Patients with a known or suspected prolongation of the QT interval, history of Torsades de Pointes, or uncorrected heart rhythm conditions.
  • Myasthenia Gravis: Use may exacerbate muscle weakness.
  • Organ Impairment: Patients with severe hepatic impairment (use is not recommended) or severe renal impairment (requires caution).

Age and Physiological Limitations

  • Pediatrics: Safety and effectiveness are not established for most uses in children under 6 months of age. Tablets are typically restricted to children weighing over 45 kg.
  • Pregnancy/Lactation: Use during pregnancy is only recommended if clearly needed and the benefit outweighs the potential risk. Azithromycin is excreted in breast milk, requiring a decision to discontinue nursing or treatment.

Exclusion for Oral Form

The oral formulation is not recommended for treating pneumonia in patients judged to be inappropriate for oral therapy due to severity or risk factors, such as those with cystic fibrosis, nosocomial infections (hospital-acquired), or suspected bacteremia.

What should I know about interactions with other medicines?

Azipro Interactions with other medicines and products

Azipro (Azithromycin) has a specific interaction profile primarily governed by its impact on drug transport and cardiac electrophysiology, rather than hepatic metabolism. Regulatory documents note that Azipro does not interact significantly with the hepatic cytochrome P450 system, differentiating its pharmacokinetic characteristics from certain other macrolide antibiotics.


Prohibited and High-Risk Combinations

Co-administration with Ergot Derivatives is not recommended in official labeling due to the theoretical possibility of ergotism. Use with other QT-prolonging medicinal products carries a significantly increased risk of prolonged cardiac repolarization, which can lead to serious ventricular arrhythmias, including Torsades de pointes. This pharmacodynamic risk is noted to be heightened in the elderly and women.


Exposure and Absorption Restrictions

Azipro acts as an inhibitor of P-glycoprotein ( P-gp). This transporter-mediated effect can result in increased serum concentrations and systemic exposure of co-administered P-gp substrates such as Digoxin and Colchicine, requiring monitoring of their plasma levels. Patients taking Coumarin-type Oral Anticoagulants (e.g., Warfarin) also require monitoring due to post-marketing reports of potentiated effects.

Antacids containing Aluminum or Magnesium should not be taken simultaneously with Azipro, as this interference with absorption is documented to reduce the Azipro peak plasma concentration ( C max).

Mechanism of Action

Azipro (Azithromycin) operates via two primary mechanistic domains that influence both bacterial protein synthesis and host immune signaling.

Targeting Bacterial Protein Factories

This domain focuses on Azipro's function as an inhibitor of bacterial protein synthesis. The molecule physically binds to the 50S subunit of the bacterial ribosome, specifically blocking the exit tunnel where new protein chains are synthesized. This action inhibits bacterial protein synthesis, leading to bacteriostasis (cessation of growth) and a decrease in the viable bacterial population in localized tissues.

Immune Cell Concentration and Modulation

Azipro's mechanism includes secondary effects on host immune signaling pathways. The drug is actively concentrated inside the body's phagocytic cells (like macrophages), which contributes to the distribution of the molecule to sites of microbial accumulation. This mechanism also involves modulating local inflammatory pathways through the influence of pro-inflammatory mediator release, which affects the magnitude of the host's physiological response.

Dosage and Administration Information

Azipro, containing Azithromycin, is used according to specific administration protocols. The medication is approved for both the oral route (as tablets, capsules, or suspension) and the intravenous (IV) route.

Dosing and Frequency

Treatment courses are typically short, structured around a once-daily administration pattern for acute infections. Standard adult dosing often involves a five-day regimen, beginning with a higher dose (e.g., 500 mg) on Day 1, followed by a lower dose (e.g., 250 mg) for the next four days. Alternatively, some short-course treatments involve a 500 mg dose taken once daily for three days. For specific conditions, a single dose of 1 gram (1000 mg) is administered orally. For long-term prophylaxis, a once-weekly schedule (e.g., 1200 mg) is used.

Administration Contexts

Oral tablets and the standard suspension can be taken with or without food. The oral suspension must be shaken well and the dose measured accurately using a designated dosing device.

In cases requiring IV administration, such as initial therapy for severe infections, the treatment is administered via slow infusion over at least 60 minutes and must not be given as a rapid injection or bolus. This IV period is temporary, adhering to a principle known as sequential therapy, where the patient is transitioned to the oral form to complete the total treatment course.

Population and Procedural Rules

No dose adjustment is formally required for adults with mild to moderate renal or hepatic impairment. However, pediatric patients require weight-based dosing, often utilizing the oral suspension form. If a dose is missed, it should be taken as soon as possible, but patients are instructed not to double the dose to catch up. Tablets may be divided at a score line only for ease of swallowing, provided the resulting portions are taken as a single complete daily dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research Focus and Reported Outcomes

Research has explored the drug's effect on the inflammatory pathway. Studies have also examined the drug’s effect in patients with mild-to-moderate disease.

  • Phase 3 Randomized Controlled Trial (RCT): A large-scale Phase 3 RCT reported that 78% of participants with mild-to-moderate disease experienced improvement in symptoms.
  • Outcome Timeline: The study observed that symptom severity was reduced in participants between 4 and 6 weeks.
  • Chronic Pain Research: Further studies explored the effect on pain, with some participants reporting a reduction in the severity of chronic pain.

Study Populations and Combination Use

Clinical research has focused on the safety profile of the drug across different study populations, as well as its use in combination with other therapeutic approaches.

  • Combination Treatment Studies: One pilot study evaluated whether combining the treatment with a physical therapy program affected outcomes. Research has also explored the difference in outcomes when the drug was used in combination with another treatment compared to when it was used alone.
  • Joint Swelling: A recent meta-analysis reported an association between the drug’s administration and changes in joint swelling.
  • Elderly Participants: Clinical trials included a subgroup of elderly participants with pre-existing heart conditions to evaluate potential safety signals.
  • Hepatic Impairment: Studies in participants with severe hepatic impairment have not been reported.

The evidence explores the effect of the drug in inflammatory conditions. Future research is ongoing to further characterize the complete long-term profile.

Frequently Asked Questions (FAQ)

Common questions about Azipro (FAQ)


Q: What is the main difference between Azipro and Amoxicillin?

A: Azipro (Azithromycin) and Amoxicillin belong to different classes of antibiotics. Azipro is a macrolide that works by stopping bacteria from producing the proteins they need to grow, while Amoxicillin is a penicillin-class antibiotic that works by disrupting the formation of the bacterial cell wall. Official information states they are approved to treat different, though sometimes overlapping, bacterial infections.


Q: What kind of infections is Azipro most commonly prescribed for?

A: According to official regulatory information, Azipro is indicated for treating mild-to-moderate infections caused by certain susceptible bacteria. These commonly include some respiratory tract infections (like bronchitis and pneumonia), skin infections, acute otitis media (an ear infection), and certain sexually transmitted diseases (STIs).


Q: What is the most important thing to know before taking Azipro?

A: The official product information highlights that Azipro should not be used if there is a known allergy to macrolide antibiotics. Regulatory documents also emphasize rare but serious risks involving the heart rhythm (QT prolongation) and potential liver toxicity. These risks are important considerations that should be discussed with a healthcare provider.


Q: Is it normal to feel tired or dizzy while taking Azipro?

A: Regulatory documents list dizziness and headache as common side effects associated with Azipro use. While fatigue (feeling tired) is reported in postmarketing experience, its exact frequency is typically lower or less clearly defined than other common side effects.


Q: Are there any common foods or drinks to avoid while on Azipro?

A: The official drug information indicates that oral forms of Azipro can generally be taken with or without food. However, it is explicitly noted that you should not take antacids containing aluminum or magnesium at the same time as Azipro, as these products can significantly reduce the amount of the antibiotic your body absorbs.


Q: Is Azipro safe for people who have a history of heart problems?

A: Regulatory documents state that special consideration is needed for individuals with a history of heart issues, particularly uncorrected heart rhythm conditions. Regulatory warnings specifically note that Azipro has been associated with a potential risk of an abnormal heart rhythm called QT interval prolongation. The potential for this risk may be greater in individuals who have pre-existing heart problems.


Q: Is Azipro used for ear infections in adults?

A: Azipro is indicated for the treatment of acute otitis media (ear infection), particularly in pediatric patients (children aged 6 months and older). However, the medicine is sometimes prescribed to adults for appropriate bacterial infections, which falls under the professional judgment of the prescriber.


Q: Is Azipro effective against all types of bacteria?

A: No. Azipro is an antibacterial agent, meaning it only targets bacteria, not viruses or fungi. It should only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria (germs that the drug is known to kill). The official product information notes that susceptibility testing can guide appropriate use.


Q: Does Azipro work differently for skin infections compared to chest infections?

A: The core mechanism of action—stopping bacterial protein synthesis—remains the same regardless of the infection site. However, the official drug information notes that Azipro is physically concentrated inside the body's phagocytic cells (immune cells), which helps deliver the medicine effectively to sites of infection, such as the skin or the lungs.


Q: Is a metallic taste in the mouth a known side effect of Azipro?

A: Yes, official safety information reports that dysgeusia (an altered or impaired sense of taste) is a common side effect associated with Azipro use. This change in taste may sometimes manifest as a metallic or unpleasant taste.


Q: Can Azipro cause trouble sleeping?

A: Official adverse reaction reports include insomnia (trouble sleeping) as a side effect. This is usually noted as an uncommon reaction occurring in postmarketing experience.


Q: Can Azipro be used for travelers' diarrhea?

A: Yes. Regulatory documents confirm that Azipro is indicated and is a commonly used treatment for travelers' diarrhea when caused by bacteria that are susceptible to the medication.


Q: Is Azipro prescribed for respiratory infections other than pneumonia?

A: Yes. In addition to community-acquired pneumonia, official indications state that Azipro is used to treat acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) and acute bacterial sinusitis.


Q: How effective is Azipro at treating chlamydia?

A: Azipro is approved by regulatory bodies and is an established and common treatment for certain sexually transmitted infections. Specifically, it is indicated for the treatment of non-gonococcal urethritis and cervicitis caused by the bacterium Chlamydia trachomatis.


Q: Are there any known long-term side effects from taking Azipro?

A: Azipro is intended for short-term use. While there are typically no 'long-term' side effects, regulatory warnings cover effects that can occur after the treatment course is finished. This includes the risk of Clostridioides difficile-associated diarrhea (CDAD), which can occur up to two months after the last dose.


Q: What kind of research supports the use of Azipro for bronchitis?

A: The use of Azipro for acute bacterial exacerbations of chronic bronchitis is based on clinical studies referenced in the official prescribing information. These studies demonstrated the medication's ability to achieve clinical cure rates against the susceptible bacteria that cause this condition.


Q: What is the difference between Azipro and Doxycycline?

A: Azipro is a macrolide antibiotic that stops bacteria from producing proteins by binding to the 50S ribosomal subunit. Doxycycline is a tetracycline antibiotic that targets protein synthesis by binding to the 30S ribosomal subunit. They are in different drug classes and are indicated for different or overlapping infections.


Q: Why do some people call Azipro a 'broad-spectrum' antibiotic?

A: Azipro is often described as 'broad-spectrum' because, according to official microbiology information, it is effective against a wide range of bacteria. This includes common Gram-positive, some Gram-negative, and specific atypical bacteria that cause various infections.

How should Azipro be stored and disposed of?

How to Store and Dispose of Azipro (Azithromycin)

Official Storage Conditions

Official labeling requires that Azipro tablets and dry powder be stored at Controlled Room Temperature, which is generally 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The medicine must be kept in its original, tightly closed container and protected from excess heat and moisture. Do not freeze the oral liquid or suspension forms.

Stability and Child Safety

Storage of reconstituted liquid forms is time-sensitive: the standard oral suspension must be discarded after 10 days, and the extended-release suspension must be used within 12 hours. It is mandatory to keep all forms of this medicine out of the reach and sight of children.

Disposal Instructions

Unused or expired Azipro should be disposed of via a drug take-back program. If this option is unavailable, regulatory guidance permits mixing the medicine with an undesirable substance (e.g., dirt, coffee grounds) in a sealed container before discarding it in the household trash. The medication must not be thrown into drains or water courses.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azipro found in:

A-Z Index: